How much bacteriostatic water suits the 5 mg vial?

Laboratory practice commonly uses 1 ml of bacteriostatic water for a 5 mg vial, giving 5 mg/ml, in which 500 mcg measures 0.1 ml — 10 units on a U-100 syringe. Because this is a small molecule rather than a peptide, aqueous solubility is limited and published studies use DMSO-containing vehicles; visual confirmation of full dissolution is advisable. The calculator on this page converts any volume and target amount into syringe units.

How stable is the reconstituted solution?

Reconstituted material is generally held for up to 28 days refrigerated at 2–8 °C and protected from light. Sealed vials are best stored at -20 °C.

What dose ranges appear in the research?

Mouse studies report roughly 50 mg per kg of bodyweight, administered intraperitoneally once or twice daily. Research-community protocol documentation describes 250–1000 mcg per administration. All figures describe research protocols, not guidance for human use.

Is this product for human use?

No. All AKH BioLabs products are supplied strictly for laboratory research. They are not approved for human consumption, and nothing on this page is medical advice.

Who tests this product?

A named laboratory outside AKH, on a report ordered by our manufacturer. The laboratory verification section on this page publishes that Certificate unaltered, or shows "Certificate pending" until a matching report has been published.

AKH Signature SLU-PP-332

Performance· AKH Signature

Sold out

SLU-PP-332

Name: SLU-PP-332
Brand: AKH BioLabs
SKU: slu-pp-332
Price: 68 USD
Availability: OutOfStock

ERR Agonist Exercise Mimetic

Size5mgPurity99.73%FormulaC20H15F3N2O3

SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, ERRγ), developed at Saint Louis University. It is classified as an "exercise mimetic" because it activates the same mitochondrial-biogenesis and fatty-acid-oxidation gene programmes triggered by aerobic training, and is studied in preclinical endurance and metabolic models.

€60

Quantity

HPLC verified

9–14 day shipping

Full COA

Worldwide delivery

About this compound

The research profile.

SLU-PP-332 is a synthetic small molecule — not a peptide — developed as a pan-agonist of the estrogen-related receptors ERRα, ERRβ, and ERRγ. It emerged from a medicinal-chemistry programme that converted an ERRβ/γ-selective agonist scaffold into compounds active at all three subtypes, and it is now widely used as a chemical probe for ERR activation.

The ERRs are orphan nuclear receptors that act as transcriptional regulators of oxidative metabolism, partnering with PGC-1α to drive mitochondrial biogenesis, fatty-acid oxidation, and the oxidative-fibre gene programme in skeletal muscle. Published work characterises SLU-PP-332 as inducing an ERRα-dependent acute aerobic exercise transcriptional response in muscle, and separate genetic work has mapped the same receptor to myofibre aerobic transformation and fuel efficiency.

The evidence base is strictly preclinical. All published in vivo characterisation of this compound has been performed in rodents by parenteral administration — the molecule is explicitly described in the literature as lacking oral bioavailability, which prompted the development of a chemically distinct successor. There are no human clinical trials of SLU-PP-332, no human pharmacokinetic data, and no established human dose.

Published research

13 peer-reviewed studies on SLU-PP-332 are summarised in our research library, including 13 published since 2023 — with study designs, reported findings and what the evidence does not establish.

Read the SLU-PP-332 evidence base

For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition.

Categorised as Performance — Mitochondrial and cellular-energy research compounds.

Dosing at a glance

What the literature reports.

For research and laboratory use only. Not for human consumption.

Route

Subcutaneous

Frequency

1–2x daily (rodent study schedules)

Reported range

250–1000 mcg

Protocol duration

2–4 weeks

250 mcgper administration1000 mcg

Published in vivo work is rodent-only and reported per kilogram of bodyweight, most commonly around 50 mg per kg given intraperitoneally once or twice daily. The 250–1000 mcg per-administration figures shown here are the amounts described in research-community protocol documentation and have no clinical basis — no human pharmacokinetic data exist for this molecule.

Ranges reflect protocols reported in the published literature on SLU-PP-332 — see research citations.

Calculate a dilution

Reconstitution & storage

From powder to solution.

Step 01
Add 1 ml bacteriostatic water
Aim the stream at the vial wall rather than the powder.
Step 02
Swirl gently — never shake
Rotate the vial until the solution runs clear. Agitation degrades the peptide.
Step 03
Refrigerate at 2–8 °C
Reconstituted vials belong in the fridge, protected from direct light.
Step 04
Use within 28 days
Discard any remainder once the stability window closes.

Lyophilised · −20 °CReconstituted · 2–8 °C, 28 days

A 5 mg vial in 2 ml gives 2.5 mg/ml. SLU-PP-332 is a small molecule rather than a peptide and has limited aqueous solubility; published in vitro and in vivo work uses DMSO-containing vehicle systems, so laboratories should confirm dissolution visually before use.

Reconstitution calculator

5 mg vial

Vial amount

Bacteriostatic water

Amount per draw

mcg

500 mcg = 0.5 mg

Draw

10units · U-100 insulin syringe

Concentration: 5 mg/ml
Draws per vial: 10
Cost per draw: €6.00

For research and laboratory use only. Not for human consumption.

Laboratory arithmetic for SLU-PP-332 — enter the COA-verified vial content for exact figures. Not medical advice.

Open the full calculator for this vial

Effect timeline

Observed across the research window.

Milestones summarise findings reported in the cited studies. Outcomes vary across models and protocols.

Start

Acute transcriptional response

The characterising study reports induction of an ERRα-dependent acute aerobic exercise gene programme in skeletal muscle within hours of administration in mice.

Week 1

Mitochondrial and respiratory measures

Preclinical work describes increased mitochondrial function and cellular respiration in treated rodent muscle across the first days of repeated administration.

Week 2–4

Whole-body metabolic end points

Metabolic-syndrome models in mice have assessed energy expenditure, fatty-acid oxidation, and body-composition measures over two-to-four-week administration periods.

End point

Scope of the evidence

All published end points for this molecule are drawn from rodent and cell-based experiments; the medicinal-chemistry record describes the parent scaffold and its subtype selectivity, and no clinical study has been reported.

Start

Acute transcriptional response

The characterising study reports induction of an ERRα-dependent acute aerobic exercise gene programme in skeletal muscle within hours of administration in mice.

Week 1

Mitochondrial and respiratory measures

Preclinical work describes increased mitochondrial function and cellular respiration in treated rodent muscle across the first days of repeated administration.

Week 2–4

Whole-body metabolic end points

Metabolic-syndrome models in mice have assessed energy expenditure, fatty-acid oxidation, and body-composition measures over two-to-four-week administration periods.

End point

Scope of the evidence

For research and laboratory use only. Not for human consumption.

Scientific research

The published evidence.

The dosing ranges and timeline milestones on this page summarise the peer-reviewed publications below.

References

01
Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chem Biol (2023). PubMed · 36988910
02
A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther (2024). PubMed · 37739806
03
Modulation of estrogen-related receptors subtype selectivity: Conversion of an ERRβ/γ selective agonist to ERRα/β/γ pan agonists. Bioorg Chem (2020). PubMed · 32683181
04
ERRα fosters running endurance by driving myofiber aerobic transformation and fuel efficiency. Mol Metab (2023). PubMed · 37802398

Laboratory verification

One Certificate, published unaltered.

The Certificate is a test report from a named laboratory outside AKH, ordered by our manufacturer and shown here exactly as the laboratory issued it. A printed copy ships in every parcel.

Batch: 26200
Test date: 31 Jul 2026
Task ID: #1812496
Purity: 99.73%

Verified by Brown Institute of Biomolecular Research. Scan the full report for every measurement.

Product FAQ